Tislelizumab

Where the papers sit

15 papers from the last 6 months study tislelizumab directly · updated from PubMed 12 Oct 2026

• Immunotherapy in Lung Cancer

  Tislelizumab-based therapy in advanced non-small cell lung cancer is expanding toward dual checkpoint blockade with ociperlimab, chemotherapy, and concurrent chemoradiotherapy. Trials focus on objective response, progression-free survival, overall survival, and patient-reported outcomes, particularly in squamous disease. Ivonescimab combinations provide an active comparative strategy rather than an established replacement. Subcutaneous formulation development and European transportability analyses are pushing treatment toward easier delivery and broader applicability.

  6 papers · 40%

• Perioperative Solid-Tumor Immunotherapy

  Tislelizumab is moving into neoadjuvant and perioperative combinations with chemotherapy across gastric, ovarian, esophageal, head and neck, and bladder cancers. Studies are linking treatment to pathological response, survival, immune-state imaging, and patient selection rather than relying on response rates alone. Ociperlimab and bevacizumab-based combinations extend this strategy beyond PD-1 blockade. Evidence remains exploratory across diverse tumors, with comparative benefit, value, and durable survival still unresolved.

  6 papers · 40%

• HER2-Positive Gastroesophageal Cancer

  HER2-positive gastroesophageal adenocarcinoma is moving toward zanidatamab-based treatment, including combination with tislelizumab to reshape the immune contexture. Gemcitabine and carboplatin remain relevant chemotherapy partners. The main open questions are whether immune remodeling improves outcomes beyond HER2 targeting and which patients benefit most. Toxic optic neuropathy highlights the need for continued safety surveillance.

  3 papers · 20%